Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia

Frances Hughes-Hubley, Mina Iskander, Angela Cheng-Lai, William H. Frishman, James Nawarskas

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Elevated plasma lipid levels, especially low-density lipoprotein, are correlated with atherosclerotic cardiovascular disease (ASCVD) and increased risk of ischemic heart disease and stroke. Statins are first-line agents for reducing low-density lipoprotein cholesterol (LDL-C) and the risk of major cardiovascular events, but patients with a genetic susceptibility or established ASCVD oftentimes remain subtherapeutic on statin therapy alone. Biotechnological advancements in medication therapy have led to the development of inclisiran, a recently approved twice-yearly injectable agent to help patients with heterozygous familial hypercholesterolemia and clinical ASCVD on a maximally tolerated statin to reach LDL-C targets. Inclisiran has demonstrated robust LDL-C reduction in clinical trials in combination with a favorable safety profile; however, the effect on cardiovascular clinical outcomes still remains under evaluation.

Original languageEnglish (US)
Pages (from-to)214-219
Number of pages6
JournalCardiology in review
Issue number4
StatePublished - Jul 1 2022


  • cholesterol
  • inclisiran
  • lipid-lowering therapy
  • small interfering ribonucleic acid
  • statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia'. Together they form a unique fingerprint.

Cite this